Published in Biochim Biophys Acta on January 27, 2006
Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep (2010) 2.93
Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res (Phila) (2010) 1.75
Functions of ocular surface mucins in health and disease. Curr Opin Allergy Clin Immunol (2008) 1.67
Interaction of Muc2 and Apc on Wnt signaling and in intestinal tumorigenesis: potential role of chronic inflammation. Cancer Res (2008) 1.52
The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis (2015) 1.33
Proteomic analyses of pancreatic cyst fluids. Pancreas (2009) 1.29
Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis (2008) 1.28
Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One (2011) 1.26
MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells. Br J Cancer (2008) 1.25
Roles of infection, inflammation, and the immune system in cholesterol gallstone formation. Gastroenterology (2008) 1.21
Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta (2011) 1.20
Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev (2010) 1.15
Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett (2011) 1.12
Tumor necrosis factor-α and Muc2 mucin play major roles in disease onset and progression in dextran sodium sulphate-induced colitis. PLoS One (2011) 1.11
Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J Proteome Res (2009) 1.11
Fusobacterium nucleatum infection of colonic cells stimulates MUC2 mucin and tumor necrosis factor alpha. Infect Immun (2011) 1.11
Tumor necrosis factor receptor 1-dependent depletion of mucus in immature small intestine: a potential role in neonatal necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol (2011) 1.06
Mucin 13: structure, function, and potential roles in cancer pathogenesis. Mol Cancer Res (2011) 1.04
Altered expression of MUC2 and MUC5AC in progression of colorectal carcinoma. World J Gastroenterol (2010) 1.03
An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum: II. Expression of MUC1, MUC2, MUC5AC, and MUC6 in normal mucosa and in 42 cases. Int J Clin Exp Pathol (2013) 0.95
Innate Immunity in the Small Intestine of the Preterm Infant. Neoreviews (2011) 0.95
An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum: III. Expressions of EMA, CEA, CA19-9, CDX-2, p53, Ki-67 antigen, TTF-1, vimentin, and p63 in normal mucosa and in 42 cases. Int J Clin Exp Pathol (2013) 0.92
Estrogen receptor-β protects against colitis-associated neoplasia in mice. Int J Cancer (2012) 0.92
Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells. Bioorg Med Chem Lett (2011) 0.90
Role of mucins in the skin during benign and malignant conditions. Cancer Lett (2010) 0.89
Mucins as diagnostic and prognostic biomarkers in a fish-parasite model: transcriptional and functional analysis. PLoS One (2013) 0.87
Mucus and adiponectin deficiency: role in chronic inflammation-induced colon cancer. Int J Colorectal Dis (2013) 0.85
Impact of kefir derived Lactobacillus kefiri on the mucosal immune response and gut microbiota. J Immunol Res (2015) 0.85
Predictive gene signatures: molecular markers distinguishing colon adenomatous polyp and carcinoma. PLoS One (2014) 0.85
Roles and regulation of the mucus barrier in the gut. Tissue Barriers (2015) 0.84
MicroRNA profiling in Muc2 knockout mice of colitis-associated cancer model reveals epigenetic alterations during chronic colitis malignant transformation. PLoS One (2014) 0.84
Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen. Oncoimmunology (2012) 0.84
Mucins and Wnt/β-catenin signaling in gastrointestinal cancers: an unholy nexus. Carcinogenesis (2016) 0.83
Differential mucin phenotypes and their significance in a variation of colorectal carcinoma. World J Gastroenterol (2013) 0.83
Glucocorticoid availability in colonic inflammation of rat. Dig Dis Sci (2007) 0.83
Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications. World J Hepatol (2015) 0.82
Muc17 protects intestinal epithelial cells from enteroinvasive E. coli infection by promoting epithelial barrier integrity. Am J Physiol Gastrointest Liver Physiol (2011) 0.81
MUC5AC interactions with integrin β4 enhances the migration of lung cancer cells through FAK signaling. Oncogene (2016) 0.80
Behavior of lactobacilli isolated from fermented slurry (ben-saalga) in gnotobiotic rats. PLoS One (2013) 0.80
SPRR2A expression in cholangiocarcinoma increases local tumor invasiveness but prevents metastasis. Clin Exp Metastasis (2013) 0.79
Salivary mucins in host defense and disease prevention. J Oral Microbiol (2015) 0.79
Characterization of cancer associated mucin type O-glycans using the exchange sialylation properties of mammalian sialyltransferase ST3Gal-II. J Proteome Res (2012) 0.79
Effect of a Semi-Purified Oligosaccharide-Enriched Fraction from Caprine Milk on Barrier Integrity and Mucin Production of Co-Culture Models of the Small and Large Intestinal Epithelium. Nutrients (2016) 0.78
Effects of galacto-oligosaccharide ingestion on the mucosa-associated mucins and sucrase activity in the small intestine of mice. Eur J Nutr (2009) 0.78
Genetically engineered mucin mouse models for inflammation and cancer. Cancer Metastasis Rev (2015) 0.78
Modifier-concept of colorectal carcinogenesis: lipidomics as a technical tool in pathway analysis. World J Gastroenterol (2010) 0.78
The Effects of Hormones and Vaginal Microflora on the Glycome of the Female Genital Tract: Cervical-Vaginal Fluid. PLoS One (2016) 0.77
Human fetal ductal plate revisited: II. MUC1, MUC5AC, and MUC6 are expressed in human fetal ductal plate and MUC1 is expressed also in remodeling ductal plate, remodeled ductal plate and mature bile ducts of human fetal livers. Int J Clin Exp Pathol (2013) 0.77
Intrauterine Growth Restriction Alters Mouse Intestinal Architecture during Development. PLoS One (2016) 0.76
Mucins and toll-like receptors: kith and kin in infection and cancer. Cancer Lett (2012) 0.76
Eukaryotic protein glycosylation: a primer for histochemists and cell biologists. Histochem Cell Biol (2016) 0.75
Lynch syndrome-associated breast cancers do not overexpress chromosome 11-encoded mucins. Mod Pathol (2013) 0.75
Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling). Biomolecules (2016) 0.75
MUC4 is negatively regulated through the Wnt/β-catenin pathway via the Notch effector Hath1 in colorectal cancer. Genes Cancer (2016) 0.75
Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis. Mediators Inflamm (2015) 0.75
Genomic alterations in mucins across cancers. Oncotarget (2017) 0.75
Expression of survivin, MUC2 and MUC5 in colorectal cancer and their association with clinicopathological characteristics. Oncol Lett (2017) 0.75
The human PAF complex coordinates transcription with events downstream of RNA synthesis. Genes Dev (2005) 2.70
Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res (2004) 2.66
Chronic pancreatic inflammation induced by environmental tobacco smoke inhalation in rats. Am J Gastroenterol (2006) 2.51
Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas (2005) 2.23
MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol (2002) 2.18
The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta (2012) 2.05
Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate (2002) 2.05
MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res (2007) 2.00
Breast cancer survival of Hispanic women in the USA is influenced by country of origin. Asia Pac J Clin Oncol (2013) 1.99
Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 1.85
Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol (2010) 1.81
MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res (2008) 1.77
Structure, evolution, and biology of the MUC4 mucin. FASEB J (2007) 1.75
Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett (2013) 1.74
Elevated serum neutrophil gelatinase-associated lipocalin is an early predictor of severity and outcome in acute pancreatitis. Am J Gastroenterol (2010) 1.65
Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res (2007) 1.61
Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms. Am J Surg Pathol (2004) 1.59
Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta (2010) 1.58
Incidence and prognostic significance of second primary cancers in renal cell carcinoma. Am J Clin Oncol (2013) 1.58
Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol (2006) 1.55
Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis (2005) 1.55
Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer (2006) 1.50
MUC4-expressing pancreatic adenocarcinomas show elevated levels of both T1 and T2 cytokines: potential pathobiologic implications. Am J Gastroenterol (2006) 1.48
MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res (2006) 1.46
Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS One (2011) 1.43
MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology (2004) 1.43
Concise review: recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells (2006) 1.40
Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate (2006) 1.40
Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol (2006) 1.39
Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med (2013) 1.38
Recent progress on tissue-resident adult stem cell biology and their therapeutic implications. Stem Cell Rev (2008) 1.36
Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Pharmacol Rev (2010) 1.33
Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci (2009) 1.31
Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia. Pancreas (2003) 1.30
Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis (2002) 1.27
Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One (2011) 1.26
Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int J Cancer (2006) 1.26
Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med (2012) 1.23
Neural invasion in the staging of pancreatic cancer. Pancreas (2003) 1.23
MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer (2006) 1.22
Engineering antibodies for clinical applications. Trends Biotechnol (2007) 1.21
Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett (2007) 1.20
Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta (2011) 1.20
Current status of mucins in the diagnosis and therapy of cancer. Biofactors (2009) 1.17
Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells. Prostate (2007) 1.17
Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol (2013) 1.17
Recent trends in antibody-based oncologic imaging. Cancer Lett (2011) 1.17
Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol Cancer Ther (2010) 1.16
Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther (2007) 1.15
Marital status and survival in pancreatic cancer patients: a SEER based analysis. PLoS One (2011) 1.14
MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Res (2008) 1.13
Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int J Oncol (2003) 1.13
Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies. Mol Med (2011) 1.13
What is the origin of pancreatic adenocarcinoma? Mol Cancer (2003) 1.11
Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol (2008) 1.11
Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res (2006) 1.10
Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res (2004) 1.10
Early detection of sporadic pancreatic cancer: summative review. Pancreas (2015) 1.10
MUC4 and MUC1 expression in adenocarcinoma of the stomach correlates with vessel invasion and lymph node metastasis: an immunohistochemical study of early gastric cancer. PLoS One (2012) 1.09
MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. Cancer Lett (2010) 1.08
Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res (2008) 1.08
Taurocholate-induced pancreatitis: a model of severe necrotizing pancreatitis in mice. Pancreas (2008) 1.07
Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies. PLoS One (2012) 1.06
Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. J Hematol Oncol (2012) 1.06
Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Cancer Lett (2012) 1.06
RNA polymerase II associated factor 1/PD2 maintains self-renewal by its interaction with Oct3/4 in mouse embryonic stem cells. Stem Cells (2009) 1.05
High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis. Int J Cancer (2010) 1.05
Characterization of human mucin MUC17. Complete coding sequence and organization. J Biol Chem (2006) 1.04
Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. Cancer Res (2005) 1.03
Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth. J Biol Chem (2010) 1.03
Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering. Anal Chem (2011) 1.03
A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol (2007) 1.03
Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin Med (2011) 1.03
Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. Clin Cancer Res (2010) 1.03
Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications. Ageing Res Rev (2008) 1.02
MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett (2009) 1.01
Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol Cancer Ther (2010) 1.01
Expression of intestinal MUC17 membrane-bound mucin in inflammatory and neoplastic diseases of the colon. J Clin Pathol (2010) 1.01
Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy. PLoS One (2013) 1.01
A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis. Oncogene (2004) 1.00
Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma. Mod Pathol (2004) 1.00
Mucin-based targeted pancreatic cancer therapy. Curr Pharm Des (2012) 1.00
Current status of the molecular genetics of human prostatic adenocarcinomas. Int J Cancer (2003) 0.99
New promising drug targets in cancer- and metastasis-initiating cells. Drug Discov Today (2010) 0.99
MUC4 potentiates invasion and metastasis of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1. Carcinogenesis (2012) 0.99
Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. Pathobiology (2012) 0.98
Induction of osteopontin expression by nicotine and cigarette smoke in the pancreas and pancreatic ductal adenocarcinoma cells. Int J Cancer (2009) 0.98
Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett (2007) 0.97
Synergistic induction of the MUC4 mucin gene by interferon-gamma and retinoic acid in human pancreatic tumour cells involves a reprogramming of signalling pathways. Oncogene (2005) 0.97